OptimizeRx

OPRX

Market cap $120M

OptimizeRx lowers 2026 revenue forecast on shifting pharma spend and managed services drag, but signals recovery ahead and stronger EBITDA expectations.

Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

ESCA, PR, MGA, OPRX and TBLA have been added to the Zacks Rank #1 (Strong Buy) List on April 1st, 2026.

TBLA, OPRX and MGA made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 1st, 2026.

OptimizeRx (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OPRX, MCY and STRA made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 24, 2026.

STRT, DXPE, ASTE, OPRX and INSP have been added to the Zacks Rank #1 (Strong Buy) List on March 24, 2026.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

OPRX, NVST and STRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 16, 2026.